Osmotic dosage forms for controlled delivery of alprazolam

Details Osmotic dosage forms for controlled delivery of alprazolam Osmotic dosage forms for controlled delivery of alprazolam

A - Human Necessities

61

K

A61K 9/22 (2006.01) A61K 9/24 (2006.01) A61K 9/36 (2006.01) A61K 9/44 (2006.01) A61K 31/5517 (2006.01)

Patent

CA 2540050

A dosage form for delivery of alprazolam is described. The sustained release dosage form provides via once-a-day dosing a therapeutically effective average steady-state plasma alprazolam concentration, where the maximum attained plasma concentration is achieved more than about 14 hours after administration. The slow, sustained release reduces side effects such as sedation and abuse potential.

L'invention concerne une forme pharmaceutique pour l'administration d'alprazolame. Cette forme pharmaceutique à libération prolongée assure par un dosage quotidien unique une concentration moyenne d'alprazolame dans le plasma en régime permanent, efficace du point de vue thérapeutique, et la concentration maximum dans le plasma est atteinte plus d'environ 14 heures après l'administration. La libération prolongée lente réduit les effets secondaires du type action sédative et potentiel d'abus.

Affiliated with

Also associated with

Rating

Osmotic dosage forms for controlled delivery of alprazolam does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Osmotic dosage forms for controlled delivery of alprazolam, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Osmotic dosage forms for controlled delivery of alprazolam will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-2012420